Back
SAB Biotherapeutics, Inc. 10K Form
Buy
71
SABS
SAB Biotherapeutics, Inc.
Last Price:
$3.54
Seasonality Move:
-14.12%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive SABS News And Ratings
See the #1 stock for the next 7 days that we like better than SABS
SABS Financial Statistics
Sales & Book Value
| Annual Sales: | $1.3M |
|---|---|
| Cash Flow: | $-13.1M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $3.48 |
| Price / Book: | 1.15 |
Profitability
| EPS (TTM): | -3.08780 |
|---|---|
| Net Income (TTM): | $-21.4M |
| Gross Margin: | $-3.5M |
| Return on Equity: | -40.88% |
| Return on Assets: | -30.39% |
SAB Biotherapeutics, Inc. Earnings Forecast
Key SAB Biotherapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 5 years for SABS is -262.42%.
-
The Selling, General & Administrative Expenses for SABS have been equal to 1,057.27% of Gross Profit Margin.
-
The Research & Development expenses have been 2,281.06% of Revenue.
-
The Net Earning history of SABS is -2,579.05% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 3 years.
SAB Biotherapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | SABS |
| Website: | sab.bio |
Debt
| Debt-to-Equity Ratio: | 0.04 |
|---|---|
| Current Ratio: | 10.5 |
| Quick Ratio: | 10.27 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
SABS Technical Analysis vs Fundamental Analysis
Buy
71
SAB Biotherapeutics, Inc. (SABS)
is a Buy
Is SAB Biotherapeutics, Inc. a Buy or a Sell?
-
SAB Biotherapeutics, Inc. stock is rated a BuyThe current SAB Biotherapeutics, Inc. [SABS] share price is $3.98. The Score for SABS is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.